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Background: The aim of the present prospective study was to examine whether lipoprotein (a) [Lp(a)] phenotypes
and/or low relative lymphocyte concentration (LRLC) are independently associated with coronary heart disease
(CHD) in patients with type 2 diabetes mellitus (T2DM).
Methods: Serum Lp(a) concentration, Lp(a) phenotypes, and RLC were analyzed in 214 subjects. Lp(a) phenotypes
were classified into 7 subtypes according to sodium dodecyl sulfate-agarose gel electrophoresis by Western blotting.
Subjects were assigned to the low-molecular-weight (LMW (number of KIV repeats: 11–22) ) and high-molecular-weight
(HMW( number of KIV repeats: >22 )) Lp(a) groups according to Lp(a) phenotype and to the LRLC (RLC: <20.3%) and
normal RLC (NRLC; RLC: ≥20.3%) groups according to RLC. A CHD event was defined as the occurrence of angina
pectoris or myocardial infarction during the follow-up period.
Results: During the follow-up period, 30 cases of CHD events were verified. Neutrophil count showed no correlation
with CHD, while relative neutrophil concentration and RLC showed positive and negative correlations, respectively,
with CHD. The Cox proportional hazard model analysis revealed the following hazard ratios adjusted for LMW Lp(a),
LRLC, and LMW Lp(a) + LRLC: (4.31; 95% confidence interval [CI], 1.99-9.32; P < 0.01, 3.621; 95% CI, 1.50-8.75; P < 0.05, and
7.15; 95% CI, 2.17-23.56; P < 0.01, respectively).
Conclusions: Our results suggest that both LMW Lp(a) and LRLC are significant and independent risk factors for CHD
and that the combination thereof more strongly predicts CHD in patients with T2DM.
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Recent studies have reported that diabetes mellitus may
correlate with coronary heart disease (CHD) [1,2]. However,
conventional risk factors for CHD in previous studies do
not account for all cases of CHD. Furthermore, epidemio-
logic studies have consistently shown a significant relation-
ship between white blood cell (WBC) counts and the onset
of CHD [3,4]. Similarly to WBC counts, relative lympho-
cyte concentration (RLC) is also a strong predictor of CHD
[5-7]. Inflammatory markers are elevated in acute coronary
syndrome (ACS), and ACS is characterized by unstable ath-
erosclerotic plaque that is activated by a systemic inflam-
matory reaction [8]. Furthermore, low RLC (LRLC) is
related to system inflammation [9]. In addition, recent stu-
dies have focused on lymphocytes (especially, RLC) and
have reported the value of this clinical parameter [10,11].
Lipoprotein (a) [Lp(a)], a plasma complex composed of
apolipoprotein (a) [apo(a)] covalently linked to apo B-100
[12], is an important risk factor for CHD [13,14]. Serum
Lp(a) is a genetically determined independent risk factor,
with a presumed variation range of ≤10% [15]. Further-
more, a recent study has shown that apo(a) has a high de-
gree of genetic polymorphism and that this polymorphism
may have a predictive value greater than serum Lp(a) con-
centration because Lp(a) phenotypes possess a genetic
trait not influenced by environmental factors as does
serum Lp(a) concentration [15]. However, this factor alone
does not fully account for the onset of CHD.
To the best of our knowledge, no study in general out-
patients with type 2 diabetes mellitus (T2DM) has exam-
ined the relationship between apo(a) phenotypes and RLC.
Therefore, we examined the effects between each Lp(a)
phenotype and RLC on the onset of CHD in patients with
T2DM during the follow-up period.
Methods
Study participants
The present prospective study enrolled 214 Japanese outpa-
tients with T2DM (115 men and 99 women) who were re-
ferred to our hospital since 1995. All subjects provided
informed consent. The present study was designed in com-
pliance with the ethic regulations set out by the Helsinki
Declaration. They underwent a standardized interview and
physical examination. Electrocardiography was performed
at baseline. In the present study, CHD was defined as the
new onset of angina pectoris or myocardial infarction dur-
ing the follow-up period. The attending physician and the
cardiologist followed the diagnostic criteria to diagnose an-
gina pectoris as an endpoint.
Myocardial infarction was diagnosed by the presence of
at least 2 of the following 3 criteria: 1) a clinical history of
central chest pressure, pain, or tightness lasting for
30 minutes or longer; 2) an ST segment elevation greater
than 0.1 mV in at least 1 standard or 2 precordial leads,an ST segment depression greater than 0.1 mV in at least 2
leads, abnormal Q wave, or T wave inversion in at least 2
leads; and 3) an increase in serum creatine kinase concen-
tration to twofold the upper limit of normal. Angina
pectoris was diagnosed based on the repeated episodes of
chest pain during an effort that usually disappeared shortly
after the cessation of the effort or the sublingual adminis-
tration of nitroglycerin. Angina pectoris was defined to
present an ST segment depression greater than 1 mm on
electrocardiograms obtained during chest pain. Patients
with T2DM were diagnosed according to the World Health
Organi-zation criteria. Patients with hypertension were de-
fined as persons who had a systolic blood pressure (SBP) of
140 mmHg or higher or a diastolic blood pressure (DBP) of
90 mmHg or higher, or who were concurrently receiving
antihypertensive drugs. Patients with dyslipidemia were
defined as persons who had a serum total cholesterol con-
centration of 220 mg/dL or higher, a serum low-density
lipoprotein cholesterol (LDL-C) concentration of 140 mg/
dL or higher, a serum triglyceride concentration of 150 mg/
dL or higher, or a serum high-density lipoprotein choles-
terol (HDL-C) concentration of 40 mg/dL or lower, or who
were concurrently receiving lipid-lowering drugs. Regarding
chronic kidney disease (CKD), the estimated glomerular fil-
tration rate was calculated as per the study of Matsuo et al.
based on the Japanese Society of Nephrology’s guidelines
for CKD, and its grades were determined [16]. HbA1c (%)
is given as National Glycohemoglobin Standardization Pro-
gram (NGSP) equivalent values (%), which were calculated
using the following formula [17]: HbA1c (%) =HbA1c
(Japan Diabetes Society; %) + 0.4%. LDL-C was calculated
using Friedewald’s formula [18].
Anthropometric measurements
The body mass index was calculated as weight (in kilo-
grams) divided by the square of height (in meters). At
screening, subjects who had never smoked and ex-smokers
were classified as nonsmokers, while those who were cur-
rently smoking were categorized as current smokers.
Exclusion criteria included a history of liver cirrhosis, tu-
berculosis, patients receiving glucocorticoids over the previ-
ous 6 weeks for rheumatoid arthritis, neoplasms, and
Basedow disease. To the extent possible, patients with heart
failure who had physical activity restrictions (NYHA II or
greater) were excluded.
Assessment of Lp(a) phenotypes and their subgroups
Serum Lp(a) concentrations were determined according to
the latex agglutination (LA) method. Within-run CVs
ranged from 1.9 to 2.1% and between-run CVs from 2.7 to
3.9% (Lp(a) Latex (Sekisui Medical, Tokyo, Japan). Apo(a)
phenotyping was performed according to sodium dodecyl
sulfate-agarose gel electrophoresis by Western blotting.
Apo(a) phenotypes were classified into 7 subtypes [F, B,
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terized by extensive size polymorphism caused by a variable
number of Kringle IV-2 (KIV-2) repeats that are transcribed
and translated into protein isoforms of different sizes [20].
Kronenberg et al. considered 11–22 and >22 KIV repeats
as LMW and HMW, respectively. A conventional cutoff
margin was established between 640 Kda and 655 Kda to
group LMW and HMW apo(a) phenotypes. The LMW
group included patients having at least one apo(a) with 11–
22 KIV repeats; the HMW group comprised patients hav-
ing only isoforms with more than 22 KIV repeats [20]. At
the commencement of the follow-up period, subjects were
assigned to either of the following two groups according to
their Lp(a) phenotypes: the LMW (F, B, S1, and S2) Lp(a)
group (number of KIV repeats: 11–22) and the HMW (S3,
S4, and O) Lp(a) group (number of KIV repeats: >22) as
previously described [21,22]. When the subject had a
double band, the faster band was used to express the
phenotype [23].
Biochemical measurements
After an overnight fast, blood samples were collected to
measure plasma blood glucose levels and serum lipid con-
centrations. Plasma glucose levels were measured according
to the glucose oxidase method. Serum concentrations of
total cholesterol, HDL-C, and triglyceride were enzymati-
cally measured with an automatic analyzer. Serum
C-reactive protein (CRP) levels were measured by latex ag-
glutination nephelometric immunoassay (LZ test ‘Eiken’
CRP-HG; Eiken Kagaku Co. Ltd, Tokyo, Japan) and with
both intra- and interassay coefficients of <1.69%. Blood
pressures were measured by the physician who used a
standard mercury sphygmomanometer, with the subject in
the sitting position after at least a 5-minute rest.
Complete blood counts were measured with an auto-
mated cell counter (SE-9000, Sysmex, Corporation, Kobe,
Japan) according to the standard techniques. Correlations
with the manual method for WBC differentials showed
good results (neutrophil %, r = 0.942; lymphocyte %,
r = 0.937) [24]. The coefficient of variation for repeated
measurements of samples from hospitalized patients was
maintained at 2.5%. RLC was defined as (total number of
lymphocytes/total number of leukocytes) × 100. The normal
range of RLC was 20.3 to 50.0%, as defined by the central
95th percentile in a population of healthy subjects [25].
Furthermore, LRLC was defined to present an RLC
of <20.3% based on previously reported reference values
[26]. Subjects were assigned to two groups according to
RLC: the low RLC (LRLC; RLC: < 20.3%) group; and the
normal RLC (NRLC; RLC: ≥ 20.3%) group.
Follow-up
Based on previous studies [10,11,27], patients were
followed up for about 7 years as a sufficient follow-upperiod. Information was also obtained for patients who no
longer underwent medical care at the hospital. Follow-up
data were obtained by the review of medical records or by
the telephone interview. We contacted the attending phy-
sician directly after obtaining patient consent to inquire
about the presence or absence of any CHD event. When
the new attending physician was not known, we contacted
the patient by telephone to inquire about his/her current
clinical condition. Regarding patients with CHD events,
we attempted to directly contact the current attending
physician. Information about 50 patients was obtained in
the above manner. No information could be obtained for
11 patients; these patients were considered withdrawals
from the study. Follow-up was discontinued for 13 pa-
tients who died of cancer (n = 6), pneumonia (n = 4), or
subarachnoid hemorrhage (n = 3).
Statistical analyses
The baseline characteristics of subjects in the two study
groups were compared by using Student’s t-test for con-
tinuous variables and the chi-square test for categorical
variables. Pearson’s correlation coefficients were used to
evaluate correlations between CHD and baseline charac-
teristics. Continuous variables were expressed as mean ±
SD. The Cox proportional hazard model was used to
investigate the relationship between the onset of CHD and
the following explanatory variables. A P-value of <0.05
was considered statistically significant. The SPSS software
(Statistical Package, version 11.0; SPSS Inc., Chicago, Il,
USA) was used for all statistical analyses.
Results
Baseline characteristics by Lp(a) phenotype of subjects in
the HMW Lp(a) group and the LMW Lp(a) group
are shown in Table 1. Serum Lp(a) was significantly higher
(P < 0.001 ) in the LMW Lp(a) group than in the HMW
Lp(a) group. Significant differences were not found be-
tween the two study groups with regard to other variables.
Furthermore, the medication rate of statins/fibrates and
the medication rate of ACE-I/ARBs were significantly
higher in the LMW Lp(a) group than in the HMW Lp(a)
group (P = 0.004 and P = 0.031, respectively). However, no
significant difference was found between the two groups
with respect to the medication rates of calcium channel
blockers (CCBs), antiplatelets, and the complication rate
of peripheral artery disease, stroke, and CKD II/III.
Baseline characteristics by RLC are shown in
Additional file 1: Table S1. Neutrophil counts and relative
neutrophil concentration were significantly higher, and
lymphocyte counts and relative monocyte concentration
and relative lymphocyte concentration were signifi-
cantly lower (P =0.001, P < 0.001, P < 0.001, P = 0.018,
P < 0.001, respectively) in the LRLC group than in the
NRLC group. Significant differences were not found





HMW Lp(a) (no. of KIV2 repeats: > 22)
group (n = 169)
LMW Lp(a) (no. of KIV 2
repeats: 11–22) group (n = 45)
P-value
Age (years) 62 ± 10 61 ± 10 65 ± 10 0.068
Gender (male/female) 105/99 93/76 22/23 0.489
White blood cells
(/mm3)
6,197 ± 1563 6,134 ± 1609 6,447 ± 1362 0.250
Neutrophil (/mm3) 3,711 ± 1223 3,677 ± 1262 3,838 ± 1057 0.433
Monocyte (/mm3) 348 ± 142 360 ± 139 399 ± 152 0.101
Basophil (/mm3) 37 ± 46 40 ± 62 34 ± 30 0.527
Eosinophil (/mm3) 173 ± 132 170 ± 126 185 ± 154 0.511
Lymphocyte
(/mm3)
1,889 ± 617 1,866 ± 601 1,973 ± 675 0.305
Neutrophil (%) 59.5 59.5 59.0 0.901
Monocyte (%) 6.0 5.9 6.3 0.353
Basophil (%) 0.6 0.6 0.5 0.302
Eosinophil (%) 2.9 2.9 2.0 0.813
Lymphocyte (%) 31.0 31.0 30.8 0.884
Systolic blood
pressure (mmHg)
138 ± 16 138 ± 17 138 ± 15 0.960
Diastolic blood
pressure (mmHg)
81 ± 10 81 ± 10 80 ± 10 0.676
Lp(a) (mg/dL) 24.1 ± 26.8 16.2 ± 13.4 53.5 ± 40.9 < 0.001
(median: range) (14.6: 0–221.0) (13.0: 0–73.3) (41.5: 8–221.0)
Total cholesterol
(mg/dL)
211 ± 39 211 ± 40 213 ± 35 0.781
HDL-C (mg/dL) 60 ± 19 61 ± 20 58 ± 17 0.492
Triglyceride (mg/dL) 134 ± 92 134 ± 93 131 ± 92 0.790
LDL-C (mg/dL) 125 ± 31 123 ± 32 129 ± 29 0.270
Creatinine (mg/dL) 1.0 ± 0.4 1.0 ± 0.4 0.9 ± 0.2 0.348
Fasting plasma
glucose (mg/dL)
166 ± 65 168 ± 66 162 ± 62 0.503
HbA1c (%) 7.9 ± 1.8 8.0 ± 1.8 7.6 ± 1.6 0.222
Body mass index
(kg/m2)
23.3 ± 4.1 23.3 ± 4.2 23.6 ± 4.0 0.665
Statins/fibrates (%) 38.8 34.1 57.8 0.004
ACE-I/ARBs (%) 22.0 18.3 35.6 0.031
CCBs (%) 27.6 26.5 33.3 0.364
Antiplatelets (%) 24.3 24.5 23.3 0.862
Peripheral vascular
disease
5.1 5.3 4.4 0.819
Stroke (%) 9.8 11.2 4.4 0.091
CKD II/III (%) 93.5 92.9 95.6 0.524
Current smoker (%) 27.5 26.0 32.5 0.412
C-reactive protein (%)§ 86.9 88.1 75.0 0.342
Values are expressed as mean ± SD or numeral (%).
HMW, high-molecular-weight; LMW, low-molecular-weight; §: Proportion of subjects with a C-reactive protein value of < 4.0 mg/L; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; ACE-I/ARBs, angiotensin- converting enzyme inhibitors/angiotensin receptor
blockers; CCBs, calcium channel blockers; CKD, chronic kidney disease.
Suzuki et al. Lipids in Health and Disease 2013, 12:31 Page 4 of 7
http://www.lipidworld.com/content/12/1/31
Table 2 Correlation coefficients of lipoprotein (a) [Lp(a)]
phenotypes, relative lymphocyt concentration, and
coronary heat disease with baseline characteristics
during follow-up
Baseline characteristics Correlation coefficients
Lp(a) phenotypes RLC CHD
Age 0.124 - 0.048 0.188**
Female gender 0.050 0.073 0.030
White blood cells (/mm3) 0.079 - 0.123 - 0.041
Neutrophil (/mm3) 0.054 - 0.380*** 0.059
Lymphocyte (/mm3) 0.071 0.414*** - 0.184**
Neutrophil (%) - 0.009 - 0.557*** 0.218**
Lymphocyte (%) - 0.010 0.568*** - 0.215**
Systolic blood pressure 0.004 - 0.014 0.137*
Diastolic blood pressure - 0.026 - 0.052 0.109
Lp(a) 0.568*** - 0.016 0.318***
Total cholesterol 0.023 0.117 - 0.081
HDL-C - 0.047 - 0.028 - 0.015
Triglyceride - 0.015 0.053 - 0.065
LDL-C 0.078 - 0.136* - 0.077
Creatinine - 0.064 - 0.008 - 0.038
Fasting plasma glucose - 0.045 - 0.070 0.080
HbA1c - 0.084 0.021 0.060
Body mass index 0.031 0.080 0.043
C-reactive protein§ - 0.072 - 0.113 0.079
Current smoker 0.058 0.078 0.165*
Statins/fibrates 0.201** - 0.008 0.145*
ACE-I/ARBs 0.165* 0.053 0.108
Antiplatelets - 0.012 - 0.120 0.184**
CKD II/III 0.044 0.045 - 0.002
Lp(a), lipoprotein (a); HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein.
cholesterol; ACE-I/ARBs, angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers; CKD, chronic kidney disease RLC, relative lymphocyte
concentration; CHD, coronary heart disease.
*P < 0.05, **P < 0.01, ***P < 0.001.
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riables. However, no significant difference was found
between the two groups with respect to the medication
rates of calcium channel blockers (CCBs), antiplatelets,
and the complication rate of peripheral artery disease,
stroke, and CKD II/III.
Correlation coefficients of baseline characteristics with
Lp(a) phenotypes, RLC, and CHD are shown in Table 2.
No correlation was found between Lp(a) phenotypes and
lymphocyte count and between Lp(a) phenotypes and RLC.
Furthermore, negative correlation was found between RLC
and neutrophil count and between RLC and relative
neutrophil concentration. Neutrophil count showed nocorrelation with CHD, while relative neutrophil concentra-
tion and RLC showed positive and negative correlations,
respectively, with CHD. We performed an ROC analysis on
CHD with respect to WBC, N (absolute number), Lym
(absolute number), % N, and % Lym. The AUC value was
slightly greater for % Lym (0.68) than for % N (0.67) and
WBC (0.493). In the present study, therefore, we selected %
Lym although both had a mirror image. No correlation was
found between Lp(a) phenotypes and baseline characteris-
tics except for statins/fibrates and ACE-I/ARBs. Therefore,
we regard both Lp(a) phenotypes and RLC as dependent
factors.
Table 3 shows the results from an analysis using the Cox
proportional hazard model of survival by CHD event du-
ring follow-up. Age, female gender, CRP, ACE-I/ARBs,
SBP, HDL-C, HbA1c, and CKD II/III were selected as vari-
ables to adjust the Cox proportional hazards based on
Table 1, Table 3, and Additional file 1: Table S1. The Cox
proportional hazard model was used to analyze LMW Lp
(a), LRLC, and LMW Lp(a) + LRLC. When not adjusted
for age, female gender, CRP, ACE-I/ARBs, SBP, HDL-C,
HbA1c, and CKD II/III, hazard ratio for LMW Lp(a),
LRLC, and LMW Lp(a) + LRLC were 4.45, 3.45, and 11.31,
respectively. When adjusted for these variables, hazard
ratio for LMW Lp(a), LRLC, and LMW Lp(a) + LRLC
were 4.31; 95% confidence interval [CI], 1.99-9.32;
P < 0.01, 3.62; 95% CI, 1.50-8.75; P < 0.05, and 7.15; 95%
CI, 2.17-23.56; P < 0.01, respectively.Discussion
Our results suggest that not only LMW Lp(a) and LRLC—
which are independent predictors for the onset of CHD—
but also the combination thereof more strongly predicts
CHD. We used the Cox proportional hazard model to
analyze LMW Lp(a), LRLC, and LMW Lp(a) + LRLC.
When not adjusted, hazard ratio for LMW Lp(a), LRLC,
and LMW Lp(a) + LRLC were, 4.45, 3.45, and 11.31
respectively. When adjusted for age, female gender, CRP,
ACE-I/ARBs, SBP, HDL-C, HbA1c, and CKD II/III, hazard
ratio for LMW Lp(a), LRLC, and LMW Lp(a) + LRLC were,
4.31, 3.62 and 7.15, respectively.
Many previous studies have reported that the inci-
dence of CHD was significantly higher in the elevated
Lp(a) group [13,14,28]. Furthermore, Lp(a) has been
reported to compete with plasminogen for the binding
sites in a dose-dependent manner. In addition, the risk
of developing CHD due to Lp(a) was attributed to the
amount of Lp(a) that was bound to small-size apo(a)
[29]. In the present study, therefore, we investigated how
Lp(a) phenotypes, but not serum Lp(a) concentrations,
might influence the onset of CHD. We also speculated
that every phenotype presents genetic polymorphism as
described by Ichinose et al. [30]. Consequently, not only
Table 3 Cox proportional hazard model of survival by coronary heat disease event during follow-up
Variables Hazard ratio (95% CI) Adjusted hazard ratio (95% CI)
LMW Lp(a) (no. of KIV2 repeats: 11–22) 4.45*** (2.18-9.11) 4.31†** (1.99-9.32)
LRLC 3.45** (1.48-8.05) 3.62†* (1.50-8.75)
LMW Lp(a) (no. of KIV2 repeats: 11–22) + LRLC 11.31*** (3.81-33.24) 7.15†** (2.17-23.56)
†Adjusted for age, female gender, CRP, ACE-I/ARBs, SBP, HDL-C, HbA1c, and CKD II/III.
CRP, C-reactive protein; ACE-I/ARBs, angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers; SBP, systolic blood pressure; HDL-C, high-density
lipoprotein cholesterol; HbA1c, glycated hemoglobin; CKD, chronic kidney disease; LMW Lp(a), low-molecular-weight lipoprotein (a); LRLC, low relative
lymphocyte concentration.
*P < 0.05, **P < 0.01, ***P < 0.001.
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were found to be associated with the onset of CHD.
We consider that LRLC is a predictor of CHD based
on its diagnostic usefulness according to previous stu-
dies (5,6,7,11), as well as on the correlation coefficients
of CHD (Table 2) and the results from the ROC analysis
about blood cell markers in the present study. Data from
experimental work in animals and in vitro data show
that leukocytes also play an important role in atheroge-
nesis [31]. Furthermore, previous investigations have
demonstrated that LRLC is also an independent pre-
dictor for CHD [5,7]. Our results indicated that subjects
with LRLC had an adjusted 3.62-fold hazard ratio of de-
veloping CHD events during follow-up and that LRLC
was an independent predictor for CHD. Our data sup-
port at least partially the role of leukocytes in the
chronic process of atherosclerosis. Although patho-
physiological mechanisms still remain unclear, current
evidence suggests that LRLC may be useful for identify-
ing patients with heart disease, e.g., ACS and heart fail-
ure. To the best of our knowledge, however, no previous
study has examined whether LMW Lp(a) and LRLC,
when combined, are strong and independent predictors
for the onset of CHD. Our study is the first to address
this issue.
According to many previous studies, the causes of
lymphocytopenia are regarded as an early marker of
stress because the stress-induced increase in cortisol se-
cretion leads to lymphocytopenia [32,33]. The mechan-
ism to induce changes in leukocyte counts probably
involves interactions among the nervous, endocrine, and
immune systems that differ from the electrical and cell-
damage mechanisms for electrocardiographic and bio-
chemical markers of infarction [6]. The hypothalamus
responds by increasing serum corticotropin-releasing
hormone levels, which then causes pulsatile increases in
serum cortisol levels.
Not only physiological stress but also mental stress has
been speculated to provoke the rupture of the fibrous cap
around coronary atherosclerotic plaque [34]. Black PH
et al. hypothesized that stress induces the release of cyto-
kines, which, together with major stress hormones—corti-
costeroids and catecholamines, induces the production ofacute phase proteins in the liver [35] and that various clas-
ses of stress can induce the production and release of
proinflammatory cytokines which may mediate micro
thrombosis.
There are several limitations to our study. First, we en-
rolled outpatients in a prospective open-label trial, which
may potentially involve attribution biases. Furthermore,
our study cannot rule out the presence of selection bias
due to its nature of being a hospital cohort study. Second,
sample size for the onset of CHD may be small. Therefore,
a multicenter study enrolling a greater number of patients
will be required in the future. Furthermore, high-
sensitivity CRP could not be measured. There is also a
need to determine the number of lymphocyte count mea-
surements by multiple measurements in the future. Third,
we did not measure serum cortisol levels to confirm its
elevation in association with a reduction in RLC. To the
extent possible, patients with heart failure (NYHA II or
greater) were excluded. However, ejection fraction (EF)
was not determined at baseline. Finally, several Lp(a) phe-
notypes are considered to exist. A further effort should be
made to determine whether other unknown Lp(a) pheno-
types may or may not correlate with the onset of CHD.
Moreover, further study using analytical procedures (e.g.,
pulse-field electrophoresis of unamplified genomic DNA)
will elucidate the effects of Lp(a) with a specified number
of KIV-2 repeats on CHD in the future.Conclusions
LMW Lp(a) is an independent risk factor for CHD, and
LRLC is also an independent risk factor of CHD. LMW
Lp(a) and LRLC, when combined, predict CHD more
strongly in patients with T2DM.
Additional file
Additional file 1: Table S1. Baseline characteristics by relative
lymphocyte concentration.
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